INmune Bio Inc.

NAS: INMB

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders

/marketstate/country/us

INmune Bio Inc.

Market closed

--Quotes are delayed by 20 min

Aug 5, 2022, 4:00 p.m.

INMB

/zigman2/quotes/206182062/composite

10.39

Change

+0.08 +0.78%

Volume

Volume 83,854

Quotes are delayed by 20 min

/zigman2/quotes/206182062/composite

Previous close

$ 10.31

$ 10.39

Change

+0.08 +0.78%

Day low

Day high

$9.99

$10.75

52 week low

52 week high

$4.63

$30.37

Income Statement Balance Sheet Cash Flow Statement

Annual Financials for INmune Bio Inc.

View Ratios

Fiscal year is January-December. All values USD millions.	2017	2018	2019	2020	2021	5-year trend
Sales/Revenue	-	-	-	10,916	181,000
Sales Growth	-	-	-	-	1,558.12%
Cost of Goods Sold (COGS) incl. D&A	-	-	-	-	-
COGS excluding D&A	-	-	-	-	-
Depreciation & Amortization Expense	-	-	-	-	-
Depreciation	-	-	-	-	-
Amortization of Intangibles	-	-	-	-	-
COGS Growth	-	-	-	-	-
Gross Income	-	-	-	-	-
Gross Income Growth	-	-	-	-	-
Gross Profit Margin	-	-	-	-	-	NA

	2017	2018	2019	2020	2021	5-year trend
SG&A Expense	981,480	12.44M	7.76M	12.24M	29.33M
Research & Development	435,362	1.11M	3.28M	5.92M	20.54M
Other SG&A	546,118	11.33M	4.47M	6.32M	-
SGA Growth	-	1,167.48%	-37.65%	57.80%	139.68%
Other Operating Expense	-	-	-	-	-
Unusual Expense	(150,000)	-	-	-	-
EBIT after Unusual Expense	(831,480)	-	-	-	-
Non Operating Income/Expense	(10)	-	-	128,520	(1.19M)
Non-Operating Interest Income	-	-	77,688	-	-
Equity in Affiliates (Pretax)	-	-	-	-	-
Interest Expense	-	-	-	-	-
Interest Expense Growth	-	-	-	-	-
Gross Interest Expense	-	-	-	-	-
Interest Capitalized	-	-	-	-	-
Pretax Income	(831,486)	(12.44M)	(7.68M)	(12.1M)	(30.34M)
Pretax Income Growth	-	-1,396.12%	38.28%	-57.58%	-150.76%
Pretax Margin	-	-	-	-	-16,762.43%	NA
Income Tax	-	-	-	-	-
Income Tax - Current Domestic	-	-	-	-	-
Income Tax - Current Foreign	-	-	-	-	-
Income Tax - Deferred Domestic	-	-	-	-	-
Income Tax - Deferred Foreign	-	-	-	-	-
Income Tax Credits	-	-	-	-	-
Equity in Affiliates	-	-	-	-	-
Other After Tax Income (Expense)	-	-	-	-	-
Consolidated Net Income	(831,486)	(12.44M)	(7.68M)	(12.1M)	(30.34M)
Minority Interest Expense	-	-	-	-	-
Net Income	(831,486)	(12.44M)	(7.68M)	(12.1M)	(30.34M)
Net Income Growth	-	-1,396.12%	38.28%	-57.58%	-150.76%
Net Margin Growth	-	-	-	-	-16,762.43%	NA
Extraordinaries & Discontinued Operations	-	-	-	-	-
Extra Items & Gain/Loss Sale Of Assets	-	-	-	-	-
Cumulative Effect - Accounting Chg	-	-	-	-	-
Discontinued Operations	-	-	-	-	-
Net Income After Extraordinaries	(831,486)	(12.44M)	(7.68M)	(12.1M)	(30.34M)
Preferred Dividends	-	-	-	-	-
Net Income Available to Common	(831,486)	(12.44M)	(7.68M)	(12.1M)	(30.34M)
EPS (Basic)	(0.07)	(1.28)	(0.75)	(1.01)	(1.88)
EPS (Basic) Growth	-	-1,623.62%	41.48%	-35.03%	-86.38%
Basic Shares Outstanding	11.22M	9.74M	10.27M	11.99M	16.13M
EPS (Diluted)	(0.07)	(1.28)	(0.75)	(1.01)	(1.88)
EPS (Diluted) Growth	-	-1,623.62%	41.48%	-35.03%	-86.38%
Diluted Shares Outstanding	11.22M	9.74M	10.27M	11.99M	16.13M
EBITDA	-	-	(7.76M)	(12.23M)	(29.15M)
EBITDA Growth	-	-	-	-57.65%	-138.42%
EBITDA Margin	-	-	-	-	-16,106.63%	NA

MarketWatch.com

Follow MarketWatch
RSS
Podcasts

Copyright © 2022 MarketWatch, Inc. All rights reserved.
By using this site, you agree to the Subscriber Agreement & Terms of Use
Privacy Notice and Cookie Notice ().
Do Not Sell My Personal Information

Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.

INmune Bio Inc.

Annual Financials for INmune Bio Inc.

Latest News

dow

nasdaq

s&p 500

Kiosk